SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Öhrfelt Annika 1973 ) srt2:(2015-2019);pers:(Portelius Erik 1977)"

Sökning: WFRF:(Öhrfelt Annika 1973 ) > (2015-2019) > Portelius Erik 1977

  • Resultat 1-3 av 3
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Olsson, Bob, 1969, et al. (författare)
  • CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis.
  • 2016
  • Ingår i: The Lancet. Neurology. - 1474-4465. ; 15:7, s. 673-684
  • Tidskriftsartikel (refereegranskat)abstract
    • Alzheimer's disease biomarkers are important for early diagnosis in routine clinical practice and research. Three core CSF biomarkers for the diagnosis of Alzheimer's disease (Aβ42, T-tau, and P-tau) have been assessed in numerous studies, and several other Alzheimer's disease markers are emerging in the literature. However, there have been no comprehensive meta-analyses of their diagnostic performance. We systematically reviewed the literature for 15 biomarkers in both CSF and blood to assess which of these were most altered in Alzheimer's disease.
  •  
2.
  • Brinkmalm-Westman, Ann, 1966, et al. (författare)
  • Explorative and targeted neuroproteomics in Alzheimer's disease.
  • 2015
  • Ingår i: Biochimica et biophysica acta. - : Elsevier BV. - 0006-3002. ; 1854:7, s. 769-778
  • Tidskriftsartikel (refereegranskat)abstract
    • Alzheimer's disease (AD) is a progressive brain amyloidosis that injures brain regions involved in memory consolidation and other higher brain functions. Neuropathologically, the disease is characterized by accumulation of a 42 amino acid peptide called amyloid β (Aβ42) in extracellular senile plaques, intraneuronal inclusions of hyperphosphorylated tau protein in neurofibrillary tangles, and neuronal and axonal degeneration and loss. Biomarker assays capturing these pathologies have been developed for use on cerebrospinal fluid samples but there are additional molecular pathways that most likely contribute to the neurodegeneration and full clinical expression of AD. One way of learning more about AD pathogenesis is to identify novel biomarkers for these pathways and examine them in longitudinal studies of patients in different stages of the disease. Here, we discuss targeted proteomic approaches to study AD and AD-related pathologies in closer detail and explorative approaches to discover novel pathways that may contribute to the disease. This article is part of a Special Issue entitled: Neuroproteomics: Applications in neuroscience and neurology.
  •  
3.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-3 av 3

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy